Gitnux/Report 2026

Fertility Industry Statistics

The global in-vitro fertilization market reached $30.1 billion in 2026, explore fertility figures on growth, companies and trends.
50Statistics
36Sources
9Sections
1Visuals
20mRead
November 18, 2026Updated
Fertility Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 38 days

01 Industry overview

The fertility industry at a glance

The global in-vitro fertilization market is projected at $30.1 billion in 2026, with demand supported by rising infertility, reproductive tourism and expanding use of embryo cryopreservation.

$30.1B[3]
Global IVF market, 2026
5.5%[3]
IVF market CAGR, 2026–2033
100,158
U.S. IVF births, 2024
37.0%[3]
Europe IVF revenue share, 2025
Market size
The global in-vitro fertilization market was valued at $28.5 billion in 2025 and is projected to reach $30.1 billion in 2026. The estimate covers IVF-related instruments, procedures, providers and regional markets.[3]
Forecast & CAGR
The market is forecast to reach $43.7 billion by 2033, representing a 5.5% compound annual growth rate from 2026 to 2033. Grand View Research identifies reproductive tourism, infertility prevalence and embryo-selection technologies as major growth factors.[3]
Market share & regions
Europe held the largest regional share, accounting for 37.0% of global IVF revenue in 2025. Separately, European clinics reported 1,156,316 ART cycles across 36 countries in 2023, including 401,483 frozen embryo-transfer cycles.[3][18]
Segmentation
The market is segmented by instrument, procedure type, provider and region. Culture media was the largest instrument segment in 2025, with approximately 41.0% of revenue, while fertility clinics were the leading provider segment.[3]
Key players & concentration
Named industry participants include Vitrolife, Boston IVF, Nova IVF, RMA Network, TFP Thames Valley Fertility, U.S. Fertility, CooperSurgical, Thermo Fisher Scientific and Ferring. In the United States, 364 fertility clinics reported data to SART for 2024; the available source does not provide a comparable market-concentration ratio.[3]
Pricing
U.S. IVF treatment costs commonly range from $12,000 to $25,000 per cycle, according to the 2025 executive order cited by the Associated Press; medications, genetic testing, storage and additional transfers can add to the total. ASRM reports that one IVF cycle represents about 50% of annual disposable household income in the United States, compared with approximately 20% in the United Kingdom and 12% in Japan.[19]
Trends, drivers & challenges
Demand is being supported by infertility, delayed parenthood, reproductive tourism and technological advances such as embryo selection, artificial intelligence and time-lapse imaging. Treatment is also shifting toward frozen embryo transfer: FET represented almost 43% of IVF-, ICSI- and FET-based European cycles in 2023, while affordability, uneven insurance coverage and access remain major challenges.[3][18]
Consumer behavior & competition
In the United States, 13.7% of women aged 20–49 had ever used fertility services in 2022–2023, including 10.4% who had used medical help to get pregnant and 1.6% who had used IVF or another ART procedure. Use varied by income: 14.8% of women in households at 450% or more of the federal poverty level had used medical help to get pregnant, compared with 5.0% below 150%.[7]
M&A
Consolidation continues through regional expansion and clinic partnerships. In November 2025, IVI RMA North America completed two transactions, including a partnership with Island Reproductive Services, an IVF clinic on Staten Island, strengthening its presence in the New York market.[20]
Regulation
U.S. ART providers are regulated at federal and state levels. The Fertility Clinic Success Rate and Certification Act of 1992 requires clinics handling human oocytes or embryos to report annual cycle characteristics and outcomes to the CDC, while laboratories are also subject to federal clinical-laboratory requirements; the 2021 national report covered 453 clinics and roughly 414,000 ART cycles.[21]
Latest news
The latest major industry milestone is the first reported year with more than 100,000 U.S. IVF births: SART-member clinics reported 449,772 IVF treatment cycles in 2024, producing 100,158 babies. In Europe, preliminary 2023 data released in July 2026 showed 1,156,316 ART cycles and 247,021 children born.[18]

02 Ranking

Top 10 Companies in the Fertility Industry

The leading companies in the fertility industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 17, 2026 · Next review December 17, 2026

Verdict

Ferring Pharmaceuticals stands out for assisted-reproduction technology medicines because it describes itself as a world leader in assisted reproductive technology medicines, while FutureLife focuses on fertility clinics and reproductive genetics since it operates 61 clinics across 15 European countries.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in assisted reproduction medicines

    Ferring Pharmaceuticals

    CH

    Ranked #1 · 9.2 · Assisted reproduction medicines

    Why we picked it: It describes itself as a world leader in assisted reproductive technology medicines.

  2. Leader in fertility clinic networks

    FutureLife

    CZ

    Ranked #2 · 9.1 · Fertility clinic networks

    Why we picked it: It operates 61 clinics across 15 European countries, focused on fertility clinics and reproductive genetics.

  3. Leader in fertility devices and services

    The Cooper Companies

    US

    Ranked #5 · 8.9 · Fertility devices and services

    Why we picked it: Its CooperSurgical unit covers fertility and women’s-health, with revenue growth of 5%.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the fertility industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Ferring Pharmaceuticals

Assisted reproduction medicines · CH

9.2
2

FutureLife

Fertility clinic networks · CZ

9.1
3

IVIRMA Global

Fertility clinic networks · ES

9.1
4

Merck KGaA

Assisted reproduction medicines · DE

8.9
5

The Cooper Companies

Fertility devices and services · US

8.9
6

CARE Fertility

UK, Ireland, Spain and US fertility clinics · GB

8.7
7

Genea

Australian fertility clinics and IVF laboratory technology · AU

8.4
8

Monash IVF Group

Australian and Southeast Asian fertility clinics · AU

8.0
9

Organon

Fertility pharmaceuticals and women's health · US

7.9
10

Indira IVF

India fertility clinics and IVF services · IN

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 17, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Henrik Dahl. (2026, February 13). Top 10 companies in the fertility industry. In Fertility Industry Statistics. Gitnux. https://gitnux.org/fertility-industry-statistics/#top-companies

report visual · Projection

Number of infants born who were conceived through assisted reproductive technology (ART), including fresh and frozen eggs or embryos from patients and donors; banking cycles excluded (United States)

Number of infants born who were conceived through assisted reproductive technology (ART), including fresh and frozen eggs or embryos from patients and donors; banking cycles excluded grew from 78K in 2017 to 98K in 2022.

78.1K count
Start
+4.72%
CAGR · 5y
98.3K count
Projected
20172022
source-verifiedcdc.gov2022

04 Statistics

Technology & AI

AI and digital-technology use is already measured across fertility workflows, with 74.9% of 167 clinic respondents reporting use in embryology laboratories in 2024 survey results.

AI and automation in the fertility industry

  • 60.82% of 171 international fertility specialists and embryologists reported at least moderate familiarity with AI in reproductive medicine in 2025.[1]
  • 74.9% of 167 fertility-clinic respondents completing at least half of a 2024 international survey reported AI or digital-technology use in embryology laboratories.[2]
  • 53.22% of 171 international fertility specialists reported regular or occasional AI use in IVF in 2025; the survey covered primarily fertility specialists and embryologists worldwide.[1]
  • 75.4% of 167 fertility-clinic respondents completing at least half of a 2024 international survey reported AI or digital-technology use in pre-treatment activities.[2]

05 Statistics

Market Intelligence

Market sizing points to a broadening service footprint beyond IVF procedures, including a global IVF services projection from $24.43 billion in 2026 to $37.46 billion by 2030.

Market size and service revenue in the fertility industry

  • $42.2 billion was the global fertility services market in 2023, covering diagnosis, treatment and preservation services delivered by fertility providers; Grand View Research estimate.[3]
  • $32.38 billion was the global fertility services market in 2025, covering fertility testing, non-ART treatment, ART, preservation and fertility-restoring surgery; Fortune Business Insights estimate.[4]
  • $11 billion or more was the U.S. fertility sector's 2023 revenue, including IVF, genetic testing, reproductive-tissue storage, donor services and medication; sector briefing estimate.[5]
  • $4.9 billion was U.S. IVF revenue in 2023 within the fertility sector's service-type segmentation; sector briefing estimate.[5]

Growth forecasts for the fertility industry

  • The global IVF services market is projected to reach $37.46 billion by 2030 from $24.43 billion in 2026, at an 11.6% CAGR for 2026–2030; category covers IVF procedures by cycle type and provider.[6]
  • The global fertility services market is projected to reach $70.99 billion by 2034 from $35.11 billion in 2026, at a 9.2% CAGR for 2026–2034; category includes ART, preservation, diagnostics and donor services.[4]
  • The global fertility services market is projected to reach $70.3 billion by 2030 from $42.2 billion in 2023, implying a 7.5% CAGR for 2024–2030; category includes diagnosis, treatment and preservation services.[3]

Firm counts and size structure in the fertility industry

  • 507 U.S. fertility clinics reported ART data to CDC for 2022; the reporting population covers clinics performing assisted reproductive technology services.[7]
  • Private-equity-affiliated U.S. fertility clinics were estimated to perform 54.0% of national IVF cycles in 2023, indicating concentration by clinic ownership group.[8]
  • 163 of 507 U.S. fertility clinics reporting 2022 data, or 32.1%, were affiliated with private equity by December 31, 2023.[8]

Demand shifts in the fertility industry

  • 184,423 U.S. ART cycles in 2022 were egg- or embryo-banking cycles with all resulting eggs or embryos frozen for future use, showing the scale of fertility-preservation demand.[7]
  • 46% of U.S. employers with at least 500 employees offered IVF coverage in 2023, up from less than one-quarter in the 2000s and 2010s, expanding employer-funded fertility-service purchasing.[9]
  • 29,803 U.S. egg-freezing cycles were reported in 2022, up from 24,560 in 2021; SART data indicate a shift toward fertility-preservation services.[9]

Regional breakdown of the fertility industry

  • 30.6% was Asia-Pacific's share of global fertility services revenue in 2025, representing $11.15 billion under the source's market definition.[10]
  • 35.0% was North America's share of global fertility services revenue in 2025, representing $12.76 billion under the source's market definition.[10]
  • 35.74% was Europe's share of global fertility services revenue in 2023; the study defines fertility services as diagnosis, treatment and preservation delivered by providers.[3]
  • 39.04% was Asia-Pacific's share of global fertility services revenue in 2025; the study includes diagnostics, ART, preservation and related fertility services.[4]

06 Statistics

Strategy & Growth

Clinic ownership is shifting in the United States, with independent U.S. fertility clinics at 44% of facilities in September 2026, down from nearly 48% in 2024.

M&A and consolidation in the fertility industry

  • Fertility-practice valuations were historically about 11x–15x EBITDA; smaller fertility deals were typically reported at 7x–9x EBITDA in 2024.[11]
  • Independent U.S. fertility clinics represented 44% of facilities in September 2026, down from nearly 48% in 2024, indicating a shift toward network ownership.[12]
  • 21 existing U.S. fertility centers changed hands between 2024 and September 2026, representing roughly 4% of the 2026 market; 14 independent clinics were acquired by networks.[12]
  • 11 fertility-services deals were agreed in North America during January–September 2024, compared with 13 in the same period of 2022, according to Mergermarket data.[11]
  • More than 50% of fertility practices were reported in 2024 to be part of a private-equity platform or university/hospital setting; the 10 largest clinical practices accounted for less than 20% of overall revenue.[11]

07 Statistics

Operating Benchmarks

U.S. ART outcomes are tracked through CDC reporting, including 435,426 ART cycles by 457 reporting clinics for 251,542 unique patients in 2022.

Operating metrics used in the fertility industry

  • 435,426 ART cycles were performed by 457 U.S. reporting clinics for 251,542 unique patients in 2022; ART cycles are procedures reported to CDC's National ART Surveillance System.[7]
  • ART-conceived infants represented approximately 2.6% of all U.S. infants born in 2022, based on CDC surveillance of reporting fertility clinics.[7]
  • 94,039 live-birth deliveries resulted from U.S. ART cycles reported for 2022; a delivery means one or more living infants born after treatment.[7]
  • 98,289 live-born infants resulted from U.S. ART cycles reported for 2022; the measure counts infants rather than delivery events.[7]

08 Statistics

Clients & Demand

Demand shows measurable adoption in the U.S., with 13.7% of women ages 20–49 reporting any fertility services in 2022–2023, including 1.6% using IVF or another ART procedure.

Service penetration and outsourcing in the fertility industry

  • 10.4% of U.S. women ages 20–49 had ever used medical help to become pregnant in 2022–2023.[7]
  • 6.9% of U.S. women ages 20–49 had ever used infertility testing for themselves or their partner in 2022–2023.[7]
  • 13.7% of U.S. women ages 20–49 had ever used any fertility services, including medical help to become pregnant or prevent pregnancy loss, in 2022–2023.[7]
  • 1.6% of U.S. women ages 20–49 had ever used in-vitro fertilization or another assisted reproductive technology procedure in 2022–2023.[7]

09 Statistics

Pricing

Pricing varies by component and total treatment planning, with $15,000–$20,000 cited as the full price of one IVF cycle in the United States in 2024.

Fees and price levels in the fertility industry

  • More than $5,000 was the reported cost of one cycle of fertility drugs in the United States in 2024.[13]
  • $15,000–$20,000 was the reported full price of one IVF cycle in the United States in 2024, excluding the possibility that patients require multiple cycles.[13]
  • $15,000–$30,000 was the estimated U.S. price of one IVF cycle in February 2024, including clinic procedures and bloodwork, fertility medications, and embryo genetic testing.[14]

10 Statistics

Finance

Ownership concentration and revenue mix show up in U.S. provider structure, with 54.0% of U.S. IVF cycles estimated to be performed by private-equity-affiliated clinics in 2023.

Ownership and investment in the fertility industry

  • 48.6% of 465 active U.S. fertility practices were independent, while 34.6% were part of fertility clinic networks and 16.8% were academic or health-system practices in 2024.[15]
  • 54.0% of U.S. IVF cycles were estimated to be performed by private-equity-affiliated fertility clinics in 2023.[8]
  • 32.1% of U.S. fertility clinics reporting to the CDC in 2022 were affiliated with private equity firms by the end of 2023.[8]

11 Statistics

Risk & Compliance

Regulatory reporting and incident tracking remain central, with 792 incidents reported to the HFEA by UK licensed clinics in financial year 2024/25, up 36% from 581 in 2023/24.

Regulation and licensing in the fertility industry

  • Treatment and storage licences may be issued for up to five years under the Human Fertilisation and Embryology Act 1990, although the HFEA says established clinics generally receive licences of up to four years; the current HFEA explanation was published in force in 2026.[16]
  • 141 clinics were licensed by the HFEA in financial year 2024/25, including 107 licensed to provide fertility treatment and 34 licensed for storage or research in the UK.[16]
  • 88 inspections identified 131 non-compliances in financial year 2024/25, averaging 1.5 non-compliances per inspection across UK licensed fertility clinics.[16]

Incidents, safety and loss events in the fertility industry

  • 14 field safety notices concerning medical devices used in UK licensed fertility clinics were issued by the HFEA in financial year 2024/25.[16]
  • 68 severe or critical ovarian hyperstimulation syndrome cases were reported by UK licensed fertility clinics in financial year 2024/25.[16]
  • 792 incidents were reported to the HFEA by UK licensed fertility clinics in financial year 2024/25, up 36% from 581 in 2023/24.[16]
  • More than 99% of approximately 100,000 fertility-treatment, storage and donation cycles occurred without a reported incident at UK licensed clinics in financial year 2024/25.[16]

12 Statistics

Market Structure

Cross-border activity is visible in U.S. ART cycle inputs, with 2.6% of 2,275,167 cycles across 182 countries attributable to non-U.S. residents during 2014–2022.

Cross-border activity and trade in the fertility industry

  • China accounted for 19,718 U.S. ART cycles during 2014–2022, compared with 6,990 cycles for Canada, the next-largest source of non-U.S. residents.[17]
  • 59,246 assisted-reproductive-technology cycles for non-U.S. residents were recorded in the United States during 2014–2022, representing 2.6% of 2,275,167 cycles across 182 countries.[17]
  • Non-U.S. residents represented 2.8% of ART cycles in U.S. clinics in 2019 before the share declined during the COVID-19 period in 2020.[17]

Key questions about the Fertility Industry

How large is the global IVF market in 2026?
The global in-vitro fertilization market is projected at $30.1 billion in 2026. The estimate includes IVF-related instruments, procedures, providers, and regional markets.
What growth rate does the IVF market show after 2026?
The IVF market is forecast to reach $43.7 billion by 2033, representing a 5.5% compound annual growth rate from 2026 to 2033. The forecast is supported by reproductive tourism, infertility prevalence, and embryo-selection technologies.
Which companies lead the fertility industry?
Ferring Pharmaceuticals stands out for assisted-reproduction technology medicines because it describes itself as a world leader in assisted reproductive technology medicines, while FutureLife focuses on fertility clinics and reproductive genetics since it operates 61 clinics across 15 European countries.
How much AI and digital technology use is reported in fertility clinics and labs?
60.82% of 171 international fertility specialists and embryologists reported at least moderate familiarity with AI in 2025. 74.9% of 167 fertility-clinic respondents reported AI or digital-technology use in embryology laboratories.
What does market structure look like in the United States for fertility clinics?
In 2024, 48.6% of 465 active U.S. fertility practices were independent, while 34.6% were part of fertility clinic networks and 16.8% were academic or health-system practices.
What share of U.S. women report using fertility services and IVF?
In 2022–2023, 13.7% of U.S. women ages 20–49 had ever used any fertility services, while 1.6% had ever used in-vitro fertilization or another assisted reproductive technology procedure.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Henrik Dahl. (2026, February 13). Fertility Industry Statistics. Gitnux. https://gitnux.org/fertility-industry-statistics
MLA
Henrik Dahl. "Fertility Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/fertility-industry-statistics.
Chicago
Henrik Dahl. 2026. "Fertility Industry Statistics." Gitnux. https://gitnux.org/fertility-industry-statistics.